Dallas, TX -- November 27, 2018 -- InvestorsHub NewsWire -- Puration, Inc. (USOTC: PURA) today announced a new CBD beverage anticipated to add over $1 million in sales not included in the recent $3 million estimated revenue projection published by Goldman Small Cap Research. Following the analyst’s estimated revenue projection, the company yesterday announced an agreement with Generex Biotechnology Corporation (OTCQB: GNBT) to develop and produce NuGenerex CBD HydroHealth High Alkaline Water. The agreement is anticipated to add over $1 million in new product sales in 2019 for Puration separate from the ongoing existing product sales that have generated approximately $1 million in reported trailing twelve-month revenue.
See the Puration and Generex Announcment:
Generex Announces NuGenerex HydroHealth CBD High Alkaline Health Water As First Target Product In Planned Line Of CBD Therapies
Puration management reports that the company has prepared for substantial growth in 2019. Among other preparations, the company’s co-packer and partner, Alkame Holdings, Inc. (USOTC: ALKM), has recently completed a state-of-the-art update to its bottling facility implementing the latest technology updates to both improve quality and significantly increase production rates. Kali, Inc. (USOTC: KALY) recently acquired Puration’s patented cannabis extraction partner, Nature Comfort Meds, and in turn, Kali has initiated work on the construction of a new inhouse lab where it will develop custom extractions for the new Generex CBD water. Management anticipates continued sales growth of its EVERx CBD Infused Sports Water in addition to adding sales in 2019 from NuGenerex CBD HydroHealth High Alkaline Water, Telluride Happy Water and THCSavor.
To learn more visit www.puraitoninc.com
About Puration, Inc.
Puration, Inc. is a leading Texas-based, CBD-infused beverage provider. The Company’s flagship product, EVERx, which was introduced in 2017, targets the sports nutrition market. Puration plans to introduce new beverages organically in addition to making targeted acquisitions.
This news release contains forward-looking statements within the meaning of the Securities Litigation Reform Act. The statements reflect the Company's current views with respect to future events that involve risks and uncertainties. Among others, these risks include the expectation that any of the companies mentioned herein will achieve significant sales, the failure to meet schedule or performance requirements of the companies' contracts, the companies' liquidity position, the companies' ability to obtain new contracts, the emergence of competitors with greater financial resources and the impact of competitive pricing. In the light of these uncertainties, the forward-looking events referred to in this release might not occur. These statements have not been evaluated by the Food and Drug Administration. These products are not intended to diagnose, treat, cure, or prevent any disease.